Clinical Trial Update: The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial (ACTION) evaluated adding Nab-paclitaxel (Abraxane) to first-line treatment for metastatic esophageal cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Esophageal Cancer, Toxicity | Phase 1, Phase 2 | Status: COMPLETED